Thermoscientific TSQ Vantage Mass Spectrometer

Thermoscientific TSQ Vantage 质谱仪

• 批准号: 7792012
• 负责人: LELAND H HARTWELL
• 金额: $ 33.54万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-06 至 2011-05-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7792012
• 关键词: Address; Area; Award; Biological; Biological Assay; Biological Markers; Biology; Biomedical Research; Cell Communication; Cells; Chromatin; Communities; Data; Detection; Development; Early Diagnosis; Ensure; Event; Faculty; Fred Hutchinson Cancer Research Center; Funding; Future; Half-Life; Hybrids; Injection of therapeutic agent; Ions; Lead; Lung; Malignant Neoplasms; Mass Spectrum Analysis; Measures; Molecular; Monitor; Outcome; Ovarian; Ovary; Pancreas; Pathway interactions; Pediatric Hospitals; Peptides; Policies; Post-Translational Protein Processing; Principal Investigator; Prostate; Protein Analysis; Proteins; Proteomics; Proteomics Shared Resource; Quality Control; Reagent; Request for Proposals; Research; Research Personnel; Role; Scanning; Serine/Threonine Phosphorylation; Serum; Signal Pathway; Signal Transduction Pathway; Technology; Treatment Efficacy; Tyrosine Phosphorylation; Ubiquitination; United States National Institutes of Health; Universities; Validation; Washington; analytical tool; anticancer research; base; cancer imaging; computer infrastructure; disease diagnosis; experience; human disease; improved; instrument; instrumentation; malignant breast neoplasm; mass spectrometer; meetings; member; multiple reaction monitoring; public health relevance; src-Family Kinases; tumor

DESCRIPTION (provided by applicant): This proposal requests funds to purchase a triple quadrupole mass spectrometer to support than 12 NIH-funded projects led by 9 principal investigators at the Fred Hutchinson Cancer Research Center (FHCRC) as well as Cancer Consortium members from the University of Washington and Children's Hospital. Projects that will benefit from this instrumentation span a variety of areas important for cancer research. Specifically the instrument will be used to understand the role of serine/threonine phosphorylation events in cell-cell communication; determine the importance of tyrosine phosphorylation events in Src kinase-modulated signaling pathways; measure the relationship between protein ubiquitination pathways and protein quality control; validate serum biomarkers in cancers of the breast, pancreas, prostate, ovary, and lung; and measure the serum half life of tumor "painting" reagents. Current mass spectrometry instrumentation at the Center (ion- trap and ion-trap/hybrid instruments) is used primarily for large proteomic profiling (e.g., discovery) studies, but is not well suited for applications that require experimental workflows that target specific molecules. Specifically, these projects require an instrument capable of performing 1) qualitative assays of specific protein modifications using precursor ion scanning and 2) highly-sensitive multiplexed quantitative assays for large numbers (100s to 1000s) of peptides in serum using Single/Multiple Reaction Monitoring (S/MRM). The triple quadrupole mass spectrometer is uniquely suited to meet these requirements. Current NIH-funded research with these requirements will demand over 2416 injections onto this instrument per year, or over 87% utilization. If awarded, the triple quadrupole instrument would be operated by the FHCRC Proteomics Shared Resource, where expertise exists to operate, maintain, and manage the instrument, and policies exist to ensure it is accessible to the entire FHCRC and Consortium community, as well as other NIH-funded investigators in the region. Moreover, the FHCRC supports a Computational Proteomics Shared Resource, managed by Center faculty who have expertise and experience to support the computational infrastructure needed to make use of the data generated by the instrument. The requested instrument will address both immediate and future needs of the user community and support NIH-funded research at the FHCRC. PUBLIC HEALTH RELEVANCE: Protein analysis by mass spectrometry is one of the most powerful and expanding analytical tools in cutting-edge biomedical research, and access to proteomics technology is critical to fully understand the biological basis of human disease and to discover and validate protein biomarkers to better diagnose disease and monitor treatment efficacy. The triple quadrupole mass spectrometer requested in this application will provide NIH funded researchers at the Fred Hutchinson Cancer Research Center critically important proteomics data for 1) the early detection of ovarian, lung, pancreatic, prostate and breast cancer through biomarker validation, 2) the development of sensitive assays to detect cancer imaging agents, and 3) the sensitive detection of protein modifications associated with signal transduction pathways, chromatin biology, protein quality control, and cell-cell communication. Ultimately, data produced from this instrument will lead to a better understanding of cancer at the molecular level and improved detection and outcomes for people afflicted with cancer.

描述（由申请人提供）：本提案申请资金购买三重四极杆质谱仪，以支持由Fred Hutchinson癌症研究中心（FHCRC）的9名首席研究员以及来自华盛顿大学和儿童医院的癌症联盟成员领导的12个nih资助的项目。将受益于这种仪器的项目涵盖了对癌症研究很重要的各个领域。具体来说，该仪器将用于了解丝氨酸/苏氨酸磷酸化事件在细胞-细胞通讯中的作用；确定酪氨酸磷酸化事件在Src激酶调节的信号通路中的重要性；测定蛋白质泛素化途径与蛋白质质量控制的关系；验证乳腺癌、胰腺癌、前列腺癌、卵巢癌和肺癌的血清生物标志物；并测定肿瘤“画”试剂的血清半衰期。该中心目前的质谱仪器（离子阱和离子阱/混合仪器）主要用于大型蛋白质组分析（例如，发现）研究，但不太适合需要针对特定分子的实验工作流程的应用。具体来说，这些项目需要一种能够进行以下工作的仪器：1)使用前体离子扫描对特定蛋白质修饰进行定性分析；2)使用单/多反应监测（S/MRM）对血清中大量（100至1000秒）肽进行高灵敏度多路定量分析。三重四极质谱计是唯一适合满足这些要求。目前美国国立卫生研究院资助的具有这些要求的研究每年将需要在该仪器上注射超过2416次，或超过87%的利用率。如果获得批准，三重四极杆仪器将由FHCRC蛋白质组学共享资源运营，该资源拥有操作、维护和管理仪器的专业知识，并有政策确保整个FHCRC和联盟社区以及该地区其他nih资助的研究人员都可以使用该仪器。此外，FHCRC支持计算蛋白质组学共享资源，由具有专业知识和经验的中心教师管理，以支持使用仪器生成的数据所需的计算基础设施。所要求的仪器将满足用户群体当前和未来的需求，并支持美国国立卫生研究院资助的FHCRC研究。